Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from Norway (341713), one (1) product patent from South Korea (10-1824154) and one (1) product patent from Singapore (11201706501V) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2027, 2034 and 2036 respectively.
The granted claims of the patents include the class of selective 5-HT6 and 5HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Narcolepsy, Parkinson and Schizophrenia respectively.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.
Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.169.2 as compared to the previous close of Rs. 167.65. The total number of shares traded during the day was 39733 in over 626 trades.
The stock hit an intraday high of Rs. 172 and intraday low of 168.1. The net turnover during the day was Rs. 6755711.